GENDER AND AGE DIFFERENCES OF BRAIN NATRIURETIC PEPTIDE CONCENTRATION IN PATIENTS WITH MYOCARDIAL INFARCTION
https://doi.org/10.15829/1560-4071-2014-7-81-86
Abstract
Aim. To measure the changes in brain natriuretic peptide (NT-proBNP) in patients with acute myocardial infarction with ST segment elevation (STEMI) according to the age and gender Material and methods. Totally 223 patients with STEMI included, of those 167 (74,88%) were men and 56 (25,11%) women. Average age of women was 61,80 (57;68) years, of men — 57,15 (51;63) years (p=0,0003). The follow-up period starting during hospitalization included 12 months of outpatient treatment. After 12 months the endpoints were assessed. The NT-proBNP concentration was measured on 10-14th day after infarction using serum by testing system "BIOMEDICA GRUPPE". Results. In women from older group NT-proBNP concentration was higher than in younger patients by 38%, in men — by 57,31%. In men with poor prognosis level of NT-proBNP was significantly higher (96,35 fM/ml) comparing to those with benign prognosis (63,8), p=0,0108. There were no such differences in women.
Conclusion. Trustworthy differences of the biomarker studied between men and women do not exist, however in men and in women either of older group (more than 65) there are higher levels of NT-proBNP, than in younger group. Also men with poor prognosis in higher age group do have the highest NT-proBNP level.
About the Authors
E. N. Usoltseva
FSBI SII of Complex Cardiovascular Diseases of the Siberian Dept of RAMS, Kemerovo, Russia.
Russian Federation
Russian Federation
E. V. Tavlueva
FSBI SII of Complex Cardiovascular Diseases of the Siberian Dept of RAMS, Kemerovo, Russia.
Russian Federation
Russian Federation
O. L. Barbarash
FSBI SII of Complex Cardiovascular Diseases of the Siberian Dept of RAMS, Kemerovo, Russia.
Russian Federation
Russian Federation
References
1. Wannamethee SG, Welsh P, Lowe GD, et al. N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without preexisting cardiovascular disease. J Am Coll Cardiol. 2011; 58:56-64.
2. Farzi S, Stojakovic T, Marko Th, et al. Role of N-terminal Pro B-type Natriuretic Peptide in Identifying Patients at High Risk for Adverse Outcome After Emergent Non-cardiac Surgery. Br J Anaesth. 2013; 110 (4):554-60.
3. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am. J. Kidney Dis. 2005; 46:610-20.
4. McCullough PA, Peacock FW, O'Neil B, et al. Capturing the pathophysiology of acute coronary syndromes with circulating biomarkers. Rev. Cardiovasc. Med. 2010; 11; Suppl. 2:3-12.
5. Drazner MN, de Lemos JA. Unexpected BNP levels in patients with advanced heart failure- a tale of caution and promise. Am. Heart J. 2005; 149:187-9.
6. PEPI Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) trial. JAMA1995; 273:199-208.
7. Lindquist P Bengtsson C, Lissner L, et al. Cholesterol and triglyceride concentration as risk factors for myocardial infarction and death in women, with special reference to influence of age. J. Intern. Med. 2002; 251, 6:484-9.
8. Orshal JM. Gender, sex hormones, and vascular tone / Orshal JM, Khalil RA. Am. J. Physiol. Regul. Integr Comp. Physiol. 2004; 286:233-49.
9. Ramcharan S. The occurrence and course of hypertensive disease in users and nonusers of oral contraceptive drug / Ramcharan S, Pellegrin FA, Hoag EJ. The Walnut Creek Contraceptive Drug Study: A Prospective Study of the Side Effects of Oral Contraceptives, vol. 2. U. S. Department of Health, Education, and Welfare Publication no. (NIH) 76-563.— Washington: DC, U.S. Government Printing Office 1976:1-16.
10. Conte MR. Gender differences in the neurohumoral control of the cardiovascular system. Ital. Heart. J. 2003; 4:367-70.
11. Pai JK, Pischon T Ma J, et al. Inflammatory Markers and the risk of coronary heart disease in men and women. N. Engl. J. Med. 2004; 351, 25:599-610.
12. Christopher BA, Timothy RW, Paul MR, et al. Multimarker approach predicts adverse cardiovascular events in women evaluated for suspected ischemia: results from the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation. Clin. Cardiol. 2009; 32, 5:244-50.
13. Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010 Mar 23; 55 (12):1266-73.
14. Schillinger M, Exner M, Mlekusch W, et al. Inflammation and Carotid Artery — Risk for Atherosclerosis Study (ICARAS). Circulation 2005; 111:2203-9.
15. Christopher BA, Timothy RW, Paul MR, et al. Multimarker approach predicts adverse cardiovascular events in women evaluated for suspected ischemia: results from the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation. Clin. Cardiol. 2009; 32, 5:244-50.
16. Alehagen U, Goetze JR, Dahlstrom U. Reference intervals and decision limits for B- type natriuretic peptide (BNP) and its precursor (NT-proBNP) in the elderly. Clin Chim Acta 2007; 382:8-14.
17. Johnston N, Jernberg T, Lindahl B, et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem 2004; 37: 210-6.
18. Krauser DG, Chen AA, Tung R, et al. Neither race nor gender influences the usefulness of amino- terminal pro-brain natriuretic peptide testing in dyspneic subjects: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. J Card Fail 2006; 12: 452-7.
19. Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89: 745-51.
20. Galasko G, Lahiri A, Barnes SC, et al. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 2005; 26 (21): 2269-76.
21. McKie P, Mayo J.B. B-type natriuretic peptide as biomarker beyond heart failure: speculations and opportunities. Clin. Proc. 2005; 80, 8:1029-36.
22. Persson H, Erntell H, Eriksson B, et al. Improved pharmacological therapy of chronic heart failure in primary care: A randomized study of NT-proBNP guided management of heart failure — SIGNAL-HF (Swedish intervention study — guidelines and NT-proBNP anaLysis in heart failure). I Eur J Heart Fail. 2010; 12 (12):1300-8.
Review
For citations:
Usoltseva E.N., Tavlueva E.V., Barbarash O.L. GENDER AND AGE DIFFERENCES OF BRAIN NATRIURETIC PEPTIDE CONCENTRATION IN PATIENTS WITH MYOCARDIAL INFARCTION. Russian Journal of Cardiology. 2014;(7):81-86. (In Russ.) https://doi.org/10.15829/1560-4071-2014-7-81-86
Views:
669
Email this article 